
-
Ikena Oncology NasdaqGM:IKNA Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Location: 645 Summer Street, Boston, MA, 02210, United States | Website: https://ikenaoncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-50.5M
Cash
114.1M
Avg Qtr Burn
-9.566M
Short % of Float
1.42%
Insider Ownership
4.55%
Institutional Own.
72.50%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma | Phase 1b Update | |
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Failed Discontinued | |
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer | Failed Discontinued |